Pharmacokinetic Evaluation of [C]CEP-32496 in Nude Mice Bearing BRAF Mutation-Induced Melanomas
CEP-32496, also known as RXDX-105 or Agerafenib, is a new orally active inhibitor for the mutated v-raf murine sarcoma viral oncogene homolog B1 (BRAF V600E ), which has attracted considerable attention in clinical trials for the treatment of human cancers. Here, we used carbon-11-labeled CEP-32496...
Main Authors: | Cuiping Jiang MMSc, Lin Xie MD, PhD, Yiding Zhang BSc, Masayuki Fujinaga PhD, Wakana Mori MSc, Yusuke Kurihara PhD, Tomoteru Yamasaki PhD, Feng Wang MD, PhD, Ming-Rong Zhang MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi - SAGE Publishing
2018-09-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012118795952 |
Similar Items
-
Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
by: Chenxing Zhang, PhD, et al.
Published: (2020-03-01) -
Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD Cell Line
by: Shuo Wang PhD, et al.
Published: (2021-09-01) -
First-In-Human Phase 1 Study of a Nonwoven Fabric Bioabsorbable Spacer for Particle Therapy: Space-Making Particle Therapy (SMPT)
by: Ryohei Sasaki, MD, PhD, et al.
Published: (2019-10-01) -
Lacrimal Sac Malignant Melanoma in 15 Japanese Patients: Case Report and Literature Review
by: Toshihiko Matsuo MD, PhD, et al.
Published: (2019-11-01) -
Asymptomatic partial regression of cerebral arteriovenous malformation without treatment: Case report and literature review
by: Tomohisa Ishida, MD, PhD, et al.
Published: (2021-03-01)